Skip to content

Incyte INCY Net Income

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+9.0%
Pfizer logo
PfizerPFE
$2.69B-9.4%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$78.69M-46.3%
Gilead Sciences logo
Gilead SciencesGILD
$2.02B+53.7%
Geron logo
GeronGERN
-$3.64M+81.6%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$3.78M+132%

Segments

By segment

See full
Reportable Segment$303.33M+91.7%

Other financials

Income statement

See full
Revenue$1.3B+20.9%
Gross profit$1.2B+19.2%
Operating income$301.1M+46.8%
EPS (diluted)$1.47+83.7%

Balance sheet

See full
Cash & equivalents$3.5B+78.2%
Total debt$39.4M-8.6%
Total equity$5.6B+53.3%
Total assets$7.3B+27.7%

Cash flow

See full
Operating cash flow$369.4M+38.8%
CapEx$1.6M-43.5%
Free cash flow$367.7M+39.7%

Valuation

See full
Market cap$23.32B+78.0%
Enterprise value$19.89B+77.9%
P/E16.3×+1.2×
P/S4.4×+1.5×

Profitability

See full
Gross margin92.5%-0.2pp
Operating margin30%+26.1pp
Net margin26.7%+26.2pp
FCF margin28.2%+19.7pp

Returns & leverage

See full
Return on equity30.8%+30.4pp
Debt / equity0.0×
Current ratio3.7×+1.6×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's net income?
Incyte (INCY) reported net income of $303.33M in Q1 2026.
How has Incyte's net income changed year-over-year?
Incyte's net income increased by 91.7% year-over-year, from $158.2M to $303.33M.
What is the long-term trend for Incyte's net income?
Over 4 years (2021 to 2025), Incyte's net income has grown at a 7.9% compound annual growth rate (CAGR), from $948.58M to $1.29B.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.